Cargando…
Exenatide extended-release; clinical trials, patient preference, and economic considerations
Type 2 diabetes remains an escalating problem worldwide, despite a range of treatments being available. The revelation that insulin secretion is under the control of a gut hormone, glucagon-like peptide 1, has led to a new paradigm in the management of type 2 diabetes, ie, use of medicines that dire...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546804/ https://www.ncbi.nlm.nih.gov/pubmed/23341736 http://dx.doi.org/10.2147/PPA.S30627 |